Personalized medicine—and personalized vaccines, in particular—have generated tremendous interest. Each vaccine must be custom-made for each patient, so for each patient more work must be done than is required for “off-the-shelf” vaccines. What are needed now are methods that enable the manufacture of such products in an affordable and efficient manner.
I’m a big fan of the singer Jack Johnson and for some reason I’ve recently had the song Inaudible Melodies in my head. The song references a story about martial artist Bruce Lee, who apparently moved so quickly that a director for one of his early films asked him to slow down. The reasoning was that he was moving faster than the individual film frames in the camera and that made his action look blurry, or out of focus. The song chorus goes like this:
BALTIMORE—Researchers at Johns Hopkins University (JHU), the University Würzburg, and the Institute of Bioinformatics (IOB)raised significant questions about current drug development assumptions
TEL AVIV, Israel—The work with the SIMAP consortium and the mitogen-activated protein kinase pathway isn’t Compugen Ltd.’s only recent advance in the area of proteomics work.
HOPKINTON, Mass.—With its agreement to acquire Xenogen Corp., Caliper Life Sciences has embarked on a critical stage to truly bring together in vitro and in vivo experimentation
BREMEN, Germany—MS specialist Bruker Daltonik announced a collaboration with the German Collection of Microorganisms and Cell Cultures (DSMZ) to identify and classify microbes from their proteomic profiles
SANTA CLARA, Calif.—Agilent Technologies announced at Pittcon 2006 last month a portfolio of internet-based services that promise to monitor its tools in the field.
WEST LAFAYETTE, Ind.—BASi and the Indiana Centers for Applied Protein Sciences (INCAPS), have agreed to bring their respective contract research strengths together in a corporate alliance
LOS ANGELES—Cedars-Sinai Medical Center’s Maxine Dunitz Neurosurgical Institute recently developed a tool to track and kill malignant brain tumor cells
GENEVA—The Drugs for Neglected Diseases Initiative (DNDi) received a €9.5-million grant from the United Kingdom’s Department of International Development (DFID)for development of drugs for tropical diseases
MALVERN, Penn.—Novavax announced a collaborative agreement with the University of Pittsburgh School of Medicine to evaluate virus-like particle (VLP) influenza vaccines and the Novasome delivery adjuvant
LAVAL, Quebec—REPLICor and NIAID Rocky Mountain Laboratories collaborated on a therapeutic that may help fight prion disorders, including mad cow and Creutzfeld-Jakob disease
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.